u/Outrageous_West_1564 · 329d agono track record yet
$GANX be careful guys!
The company's mitochondria-first Parkinson's thesis lacks rigor, relying on N=1 data with statistically insignificant improvements. Placebo effects in Parkinson's trials are notoriously strong (20-30%), and the sector graveyard is full of promising preclinical candidates that failed in blinded trials, including Sanofi's Venglustat and antibodies from Roche and Biogen.
At post $3.99Now $1.13-71.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+1.5%
1w+3.8%
1m-25.6%
3m-23.6%
6m-53.4%
1y—